Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging.

Epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER-1) is a membrane bound protein that has been associated with a variety of solid tumors and the control of cell survival, proliferation, and metabolism. Quantification of the EGFR expression level in cell membranes and the interaction kinetics with drugs are thus important for cancer diagnosis and treatment. Here we report mapping of the distribution and interaction kinetics of EGFR in their native environment with the surface plasmon resonance imaging (SPRi) technique. The monoclonal anti-EGFR antibody was used as a model drug in this study. The binding of the antibody to EGFR overexpressed A431 cells was monitored in real time, which was found to follow the first-order kinetics with an association rate constant (ka) and dissociation rate constant (kd) of (2.7 ± 0.6) × 10(5) M(-1) s(-1) and (1.4 ± 0.5) × 10(-4) s(-1), respectively. The dissociation constant (KD) was determined to be 0.53 ± 0.26 nM with up to seven-fold variation among different individual A431 cells. In addition, the averaged A431 cell surface EGFR density was found to be 636/μm(2) with an estimation of 5 × 10(5) EGFR per cell. Additional measurement also revealed that different EGFR positive cell lines (A431, HeLa, and A549) show receptor density dependent anti-EGFR binding kinetics. The results demonstrate that SPRi is a valuable tool for direct quantification of membrane protein expression level and ligand binding kinetics at single cell resolution. Our findings show that the local environment affects the drug-receptor interactions, and in situ measurement of membrane protein binding kinetics is important.

[1]  J. Benovic,et al.  Modulation of the Arrestin-Clathrin Interaction in Cells , 1997, The Journal of Biological Chemistry.

[2]  A. Maity,et al.  Cellular responses to EGFR inhibitors and their relevance to cancer therapy. , 2007, Cancer letters.

[3]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[4]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[5]  Xiaobo Yu,et al.  In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance , 2014, Scientific Reports.

[6]  R. Corn,et al.  Detection of protein biomarkers using RNA aptamer microarrays and enzymatically amplified surface plasmon resonance imaging. , 2007, Analytical chemistry.

[7]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[8]  Roy S Herbst,et al.  Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.

[9]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[10]  Igor L. Medintz,et al.  Quantum dot bioconjugates for imaging, labelling and sensing , 2005, Nature materials.

[11]  R. Tsien,et al.  The Fluorescent Toolbox for Assessing Protein Location and Function , 2006, Science.

[12]  Yunze Yang,et al.  Label-free measuring and mapping of binding kinetics of membrane proteins in single living cells. , 2012, Nature chemistry.

[13]  C. Arteaga Epidermal growth factor receptor dependence in human tumors: more than just expression? , 2002, The oncologist.

[14]  Jerry M Maniate,et al.  Targeting the EGFR pathway for cancer therapy. , 2006, Current medicinal chemistry.

[15]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[16]  Peter Wiktor,et al.  Measurement of Small Molecule Binding Kinetics on a Protein Microarray by Plasmonic-Based Electrochemical Impedance Imaging , 2014, Analytical chemistry.

[17]  P M Harari,et al.  Epidermal growth factor receptor inhibition strategies in oncology. , 2004, Endocrine-related cancer.

[18]  N. Normanno,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? , 2006, Endocrine-related cancer.

[19]  M. Malmqvist,et al.  BIACORE: an affinity biosensor system for characterization of biomolecular interactions. , 1999, Biochemical Society transactions.

[20]  R. Herbst,et al.  IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. , 2002, Expert opinion on biological therapy.

[21]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[22]  J. Grandis,et al.  Signaling through the epidermal growth factor receptor during the development of malignancy. , 2004, Pharmacology & therapeutics.

[23]  Aaron R. Halpern,et al.  Near infrared surface plasmon resonance phase imaging and nanoparticle-enhanced surface plasmon resonance phase imaging for ultrasensitive protein and DNA biosensing with oligonucleotide and aptamer microarrays. , 2012, Analytical Chemistry.

[24]  Sara Linse,et al.  Methods for the detection and analysis of protein–protein interactions , 2007, Proteomics.

[25]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[26]  H. Lenz,et al.  EGFR, HER2 and VEGF Pathways , 2012, Drugs.

[27]  M. Nakamoto,et al.  Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines , 2007, Clinical Cancer Research.

[28]  John Mendelsohn,et al.  The EGF receptor family as targets for cancer therapy , 2000, Oncogene.

[29]  F. Ciardiello Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents , 2012, Drugs.

[30]  E. Butcher Can cell systems biology rescue drug discovery? , 2005, Nature Reviews Drug Discovery.

[31]  D. Swinney The role of binding kinetics in therapeutically useful drug action. , 2009, Current opinion in drug discovery & development.

[32]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[33]  S. Gan,et al.  Enzyme immunoassay and enzyme-linked immunosorbent assay. , 2013, The Journal of investigative dermatology.

[34]  Yuyuan Tian,et al.  Charge-based detection of small molecules by plasmonic-based electrochemical impedance microscopy. , 2013, Analytical chemistry.

[35]  R. Schasfoort,et al.  Handbook of surface plasmon resonance , 2008 .

[36]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[37]  Roy S Herbst,et al.  Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. , 2002, Seminars in oncology.

[38]  Wei Wang,et al.  Plasmonic imaging of protein interactions with single bacterial cells. , 2015, Biosensors & bioelectronics.

[39]  Targeted therapy in non-small-cell lung cancer. , 2002, Oncology.

[40]  Konstantin A Lukyanov,et al.  Fluorescent proteins as a toolkit for in vivo imaging. , 2005, Trends in biotechnology.

[41]  B. Schoeberl,et al.  Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies , 2012, Molecular Cancer Therapeutics.

[42]  B. Haab Methods and applications of antibody microarrays in cancer research , 2003, Proteomics.

[43]  C. Arteaga,et al.  Tyrosine kinase inhibitors—ZD1839 (Iressa) , 2001, Current opinion in oncology.

[44]  Aaron R. Halpern,et al.  On-chip synthesis of protein microarrays from DNA microarrays via coupled in vitro transcription and translation for surface plasmon resonance imaging biosensor applications. , 2012, Journal of the American Chemical Society.

[45]  M. Trevethick,et al.  Ligand binding assays at equilibrium: validation and interpretation , 2010, British journal of pharmacology.

[46]  R. Corn,et al.  On-chip synthesis of RNA aptamer microarrays for multiplexed protein biosensing with SPR imaging measurements. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[47]  Y. Yarden The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[48]  J. Baselga Why the epidermal growth factor receptor? The rationale for cancer therapy. , 2002, The oncologist.

[49]  J. Baselga,et al.  Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.